Cargando…

Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms

Carbapenem-resistant Enterobacterales (CRE) and Pseudomonas aeruginosa (CR-PA) producing metallo-β-lactamases (MBLs) cause severe nosocomial infections with no defined treatment. The combination of aztreonam (ATM) with ceftazidime-avibactam (CZA) is a potential therapeutic option, but there is no ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Ayesha, Erickson, Samuel G., Pettaway, Cedric, Arias, Cesar A., Miller, William R., Bhatti, Micah M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522751/
https://www.ncbi.nlm.nih.gov/pubmed/34424044
http://dx.doi.org/10.1128/AAC.00846-21
_version_ 1784585152091914240
author Khan, Ayesha
Erickson, Samuel G.
Pettaway, Cedric
Arias, Cesar A.
Miller, William R.
Bhatti, Micah M.
author_facet Khan, Ayesha
Erickson, Samuel G.
Pettaway, Cedric
Arias, Cesar A.
Miller, William R.
Bhatti, Micah M.
author_sort Khan, Ayesha
collection PubMed
description Carbapenem-resistant Enterobacterales (CRE) and Pseudomonas aeruginosa (CR-PA) producing metallo-β-lactamases (MBLs) cause severe nosocomial infections with no defined treatment. The combination of aztreonam (ATM) with ceftazidime-avibactam (CZA) is a potential therapeutic option, but there is no approved, feasible testing method for use in clinical laboratories to assess the activity of two antimicrobials in combination. Here, we evaluate the performance of four ATM-CZA combination testing methods, as follows: broth disk elution (DE), disk stacking (DS), strip stacking (SS), and strip crossing (SX). We used 10 clinical, representative Enterobacterales and 6 P. aeruginosa isolates harboring MBL, Guiana extended-spectrum beta-lactamase (GES), or non-MBL enzymes. Four of these isolates were from clinical cases treated by ATM-CZA. All CRE producing NDM and CR-PA producing GES that were resistant to ATM and CZA alone were susceptible to the ATM-CZA combination. P. aeruginosa generating NDM or VIM remained resistant to ATM-CZA, likely due to non-β-lactamase mechanisms, and all other isolates were susceptible to ATM or CZA alone. The most accurate, precise, and reproducible methods of low complexity were disc elution and both strip methods (SX and SS) using MIC test strips (MTS) , all with 100% sensitivity and specificity, followed by Etest with SX (95.83% sensitivity, 100% specificity) and SS (87.5% sensitivity, 100% specificity). DS had the lowest performance. DE is particularly valuable in low-resource settings that routinely use disks. MTS yielded higher categorical agreements by SX (94%) and SS (84%), relative to Etest by SX (90%) and SS (82%). P. aeruginosa results yielded the majority of the errors. These methods may allow laboratories to inform clinical decision making like combination therapy for severe infections caused by extensively drug-resistant Enterobacterales.
format Online
Article
Text
id pubmed-8522751
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-85227512021-10-20 Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms Khan, Ayesha Erickson, Samuel G. Pettaway, Cedric Arias, Cesar A. Miller, William R. Bhatti, Micah M. Antimicrob Agents Chemother Susceptibility Carbapenem-resistant Enterobacterales (CRE) and Pseudomonas aeruginosa (CR-PA) producing metallo-β-lactamases (MBLs) cause severe nosocomial infections with no defined treatment. The combination of aztreonam (ATM) with ceftazidime-avibactam (CZA) is a potential therapeutic option, but there is no approved, feasible testing method for use in clinical laboratories to assess the activity of two antimicrobials in combination. Here, we evaluate the performance of four ATM-CZA combination testing methods, as follows: broth disk elution (DE), disk stacking (DS), strip stacking (SS), and strip crossing (SX). We used 10 clinical, representative Enterobacterales and 6 P. aeruginosa isolates harboring MBL, Guiana extended-spectrum beta-lactamase (GES), or non-MBL enzymes. Four of these isolates were from clinical cases treated by ATM-CZA. All CRE producing NDM and CR-PA producing GES that were resistant to ATM and CZA alone were susceptible to the ATM-CZA combination. P. aeruginosa generating NDM or VIM remained resistant to ATM-CZA, likely due to non-β-lactamase mechanisms, and all other isolates were susceptible to ATM or CZA alone. The most accurate, precise, and reproducible methods of low complexity were disc elution and both strip methods (SX and SS) using MIC test strips (MTS) , all with 100% sensitivity and specificity, followed by Etest with SX (95.83% sensitivity, 100% specificity) and SS (87.5% sensitivity, 100% specificity). DS had the lowest performance. DE is particularly valuable in low-resource settings that routinely use disks. MTS yielded higher categorical agreements by SX (94%) and SS (84%), relative to Etest by SX (90%) and SS (82%). P. aeruginosa results yielded the majority of the errors. These methods may allow laboratories to inform clinical decision making like combination therapy for severe infections caused by extensively drug-resistant Enterobacterales. American Society for Microbiology 2021-10-18 /pmc/articles/PMC8522751/ /pubmed/34424044 http://dx.doi.org/10.1128/AAC.00846-21 Text en Copyright © 2021 Khan et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Susceptibility
Khan, Ayesha
Erickson, Samuel G.
Pettaway, Cedric
Arias, Cesar A.
Miller, William R.
Bhatti, Micah M.
Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms
title Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms
title_full Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms
title_fullStr Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms
title_full_unstemmed Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms
title_short Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms
title_sort evaluation of susceptibility testing methods for aztreonam and ceftazidime-avibactam combination therapy on extensively drug-resistant gram-negative organisms
topic Susceptibility
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522751/
https://www.ncbi.nlm.nih.gov/pubmed/34424044
http://dx.doi.org/10.1128/AAC.00846-21
work_keys_str_mv AT khanayesha evaluationofsusceptibilitytestingmethodsforaztreonamandceftazidimeavibactamcombinationtherapyonextensivelydrugresistantgramnegativeorganisms
AT ericksonsamuelg evaluationofsusceptibilitytestingmethodsforaztreonamandceftazidimeavibactamcombinationtherapyonextensivelydrugresistantgramnegativeorganisms
AT pettawaycedric evaluationofsusceptibilitytestingmethodsforaztreonamandceftazidimeavibactamcombinationtherapyonextensivelydrugresistantgramnegativeorganisms
AT ariascesara evaluationofsusceptibilitytestingmethodsforaztreonamandceftazidimeavibactamcombinationtherapyonextensivelydrugresistantgramnegativeorganisms
AT millerwilliamr evaluationofsusceptibilitytestingmethodsforaztreonamandceftazidimeavibactamcombinationtherapyonextensivelydrugresistantgramnegativeorganisms
AT bhattimicahm evaluationofsusceptibilitytestingmethodsforaztreonamandceftazidimeavibactamcombinationtherapyonextensivelydrugresistantgramnegativeorganisms